Semler Scientific (SMLR)
(Delayed Data from NSDQ)
$22.92 USD
-0.04 (-0.17%)
Updated May 10, 2024 04:00 PM ET
After-Market: $22.90 -0.02 (-0.09%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
SMLR 22.92 -0.04(-0.17%)
Will SMLR be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for SMLR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SMLR
After Plunging 30.3% in 4 Weeks, Here's Why the Trend Might Reverse for Semler Scientific Inc. (SMLR)
Semler Scientific Inc. (SMLR) Q3 Earnings Beat Estimates
SMLR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Chemed (CHE) Roto-Rooter Business Grows, VITAS Admission Dips
Here's Why Investors Should Hold Exact Sciences (EXAS) Stock
Boston Scientific (BSX) Benefits From New Buyouts, FX Woes Stay
Other News for SMLR
Semler Scientific’s Financial Ambiguity: The Risks of an Undefined Capital Allocation Strategy
Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
Semler Scientific: Great Product Can Still Thrive Post Medicare Advantage
Lake Street Remains a Buy on Semler Scientific (SMLR)